Order Sucraid®
Important Safety Information
Prescribing Information
Patient Site

Try a 4-Day Trial
 of Sucraid®

Have patients suffering 
from chronic, unresolved 
IBS-like symptoms? 
Could it be CSID?

CSID is a genetic disease characterized by the inability to digest and absorb sugar (sucrose) and starch.
Download Trial Order Form
Learn how to order Sucraid® from our specialty pharmacy.

What is Sucraid®?

Sucraid® is an enzyme replacement therapy that contains sacrosidase as a substitute for sucrase, which is one of the enzymes that is defective in individuals who have Congenital Sucrase-Isomaltase Deficiency (CSID). Sacrosidase facilitates the breakdown of sucrose (sugar) into its constituent monosaccharide units, glucose and fructose, for absorption from the small intestine. Sucraid® has been documented to help relieve the gastrointestinal symptoms associated with CSID, and as a result, help affected individuals consume a more normal diet that includes sucrose-containing foods.

Read More

What are you 
missing? Could it be CSID?

Congenital Sucrase-Isomaltase Deficiency (CSID), also known as Genetic Sucrase-Isomaltase Deficiency (GSID), is an autosomal recessive disorder that causes a deficiency in sucrase-isomaltase (SI), the enzyme responsible for the metabolism of sucrose and other sugars found in starch, and the subsequent absorption of their metabolites, glucose and fructose.

Read More

How to
diagnose CSID

CSID is largely a clinical diagnosis, but there are diagnostic tools to assess sucrase enzyme activity.

Diagnosing CSID

How to order
Sucraid®

Sucraid® is only available through an exclusive specialty pharmacy provider that ships the therapy directly to the patient’s home or physician’s office.

How to Order

Sucraid® treats CSID. 
The only FDA-approved 
enzyme replacement therapy.

Try a 4-Day Trial
 of Sucraid®.

 Download the Sucraid 4-Day Trial Rx form
 and see if Sucraid® is right for your patients.

Sucraid® 
mechanism of action

About Sucraid®

In clinical trials, 81% of patients
became asymptomatic* 
with Sucraid®.1

*Patients who took Sucraid® with each meal were considered asymptomatic if reported no GI symptoms for at least 7 of the 10 study days.

Proper dosing 
is essential!

The proper Sucraid® dose depends on the patient’s body weight.

Learn more about 
CSID and Sucraid®

Learn more about
CSID in children

Explore

Important information
for healthcare
professionals

Explore

Learn more about
CSID in adults

Explore

Dr. William Chey

Download templates 
for Letters of Medical Necessity

Biopsy

Genetic Test

History

Activity

RX Trial

Our specialty
pharmacy

Learn how to order Sucraid®
from our specialty pharmacy.

How to Order
References
  1. Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 1999;28(2):137-142. doi:10.1097/00005176-199902000-00008
Important Safety Information
Sucraid® (sacrosidase) Oral Solution
  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.
Indication
Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

IMPORTANT SAFETY INFORMATION:

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.